Benzinga's Top Ratings Upgrades, Downgrades For November 16, 2022

Upgrades

• According to Janney Montgomery Scott, the prior rating for Consolidated Water Co Ltd (NASDAQ:CWCO) was changed from Neutral to Buy. In the third quarter, Consolidated Water Co showed an EPS of $0.05, compared to $0.09 from the year-ago quarter. The stock has a 52-week-high of $20.58 and a 52-week-low of $9.01. At the end of the last trading period, Consolidated Water Co closed at $13.70.
• According to Benchmark, the prior rating for Tencent Music Entertainment Group (NYSE:TME) was changed from Hold to Buy. In the third quarter, Tencent Music Enter Gr showed an EPS of $0.12, compared to $0.09 from the year-ago quarter. The stock has a 52-week-high of $7.66 and a 52-week-low of $2.95. At the end of the last trading period, Tencent Music Enter Gr closed at $5.81.
• For Lincoln National Corp (NYSE:LNC), Goldman Sachs upgraded the previous rating of Neutral to Buy. For the third quarter, Lincoln National had an EPS of $1.39, compared to year-ago quarter EPS of $1.62. The stock has a 52-week-high of $76.40 and a 52-week-low of $32.59. At the end of the last trading period, Lincoln National closed at $34.16.
• Deutsche Bank upgraded the previous rating for Cabot Corp (NYSE:CBT) from Hold to Buy. For the fourth quarter, Cabot had an EPS of $1.55, compared to year-ago quarter EPS of $1.11. At the moment, the stock has a 52-week-high of $78.62 and a 52-week-low of $53.32. Cabot closed at $72.75 at the end of the last trading period.
• Atlantic Equities upgraded the previous rating for Xylem Inc (NYSE:XYL) from Neutral to Overweight. Xylem earned $0.79 in the third quarter, compared to $0.63 in the year-ago quarter. The stock has a 52-week-high of $121.05 and a 52-week-low of $72.08. At the end of the last trading period, Xylem closed at $112.13.
• Wells Fargo upgraded the previous rating for Oscar Health Inc (NYSE:OSCR) from Equal-Weight to Overweight. Oscar Health earned $0.91 in the third quarter, compared to $1.02 in the year-ago quarter. At the moment, the stock has a 52-week-high of $10.53 and a 52-week-low of $2.34. Oscar Health closed at $2.89 at the end of the last trading period.

See all analyst ratings upgrades.

Downgrades

• Chardan Capital downgraded the previous rating for Evelo Biosciences Inc (NASDAQ:EVLO) from Buy to Neutral. Evelo Biosciences earned $0.28 in the third quarter, compared to $0.63 in the year-ago quarter. At the moment, the stock has a 52-week-high of $6.83 and a 52-week-low of $1.42. Evelo Biosciences closed at $2.19 at the end of the last trading period.
• B. Riley Securities downgraded the previous rating for Spectrum Pharmaceuticals Inc (NASDAQ:SPPI) from Buy to Neutral. Spectrum Pharmaceuticals earned $0.12 in the third quarter, compared to $0.16 in the year-ago quarter. The current stock performance of Spectrum Pharmaceuticals shows a 52-week-high of $1.62 and a 52-week-low of $0.36. Moreover, at the end of the last trading period, the closing price was at $0.52.
• According to UBS, the prior rating for Advance Auto Parts Inc (NYSE:AAP) was changed from Buy to Neutral. In the third quarter, Advance Auto Parts showed an EPS of $2.84, compared to $3.21 from the year-ago quarter. At the moment, the stock has a 52-week-high of $244.55 and a 52-week-low of $154.46. Advance Auto Parts closed at $183.94 at the end of the last trading period.
• For Rocket Companies Inc (NYSE:RKT), Argus Research downgraded the previous rating of Hold to Sell. In the third quarter, Rocket Companies showed an EPS of $0.08, compared to $0.57 from the year-ago quarter. The stock has a 52-week-high of $15.26 and a 52-week-low of $5.97. At the end of the last trading period, Rocket Companies closed at $8.38.
• JonesTrading downgraded the previous rating for Inhibikase Therapeutics Inc (NASDAQ:IKT) from Buy to Hold. In the third quarter, Inhibikase Therapeutics showed an EPS of $0.18, compared to $0.18 from the year-ago quarter. The current stock performance of Inhibikase Therapeutics shows a 52-week-high of $1.80 and a 52-week-low of $0.44. Moreover, at the end of the last trading period, the closing price was at $0.62.
• For Winc Inc (AMEX:WBEV), Canaccord Genuity downgraded the previous rating of Buy to Hold. In the third quarter, Winc showed an EPS of $0.33, compared to $2.55 from the year-ago quarter. The current stock performance of Winc shows a 52-week-high of $8.66 and a 52-week-low of $0.40. Moreover, at the end of the last trading period, the closing price was at $0.45.
• According to B. Riley Securities, the prior rating for Infinity Pharmaceuticals Inc (NASDAQ:INFI) was changed from Buy to Neutral. In the third quarter, Infinity Pharmaceuticals showed an EPS of $0.12, compared to $0.12 from the year-ago quarter. At the moment, the stock has a 52-week-high of $2.41 and a 52-week-low of $0.46. Infinity Pharmaceuticals closed at $0.79 at the end of the last trading period.
• For Evotec SE (NASDAQ:EVO), Deutsche Bank downgraded the previous rating of Buy to Hold. At the moment, the stock has a 52-week-high of $23.63 and a 52-week-low of $7.83. Evotec closed at $9.25 at the end of the last trading period.
• For Sotera Health Co (NASDAQ:SHC), Barclays downgraded the previous rating of Equal-Weight to Underweight. For the third quarter, Sotera Health had an EPS of $0.23, compared to year-ago quarter EPS of $0.21. The current stock performance of Sotera Health shows a 52-week-high of $24.90 and a 52-week-low of $5.78. Moreover, at the end of the last trading period, the closing price was at $6.97.
• For Unum Group (NYSE:UNM), Goldman Sachs downgraded the previous rating of Buy to Neutral. In the third quarter, Unum showed an EPS of $1.51, compared to $1.03 from the year-ago quarter. The stock has a 52-week-high of $46.64 and a 52-week-low of $24.23. At the end of the last trading period, Unum closed at $40.55.
• According to Oppenheimer, the prior rating for Evoqua Water Technologies Corp (NYSE:AQUA) was changed from Outperform to Perform. For the fourth quarter, Evoqua Water Technologies had an EPS of $0.45, compared to year-ago quarter EPS of $0.31. At the moment, the stock has a 52-week-high of $48.49 and a 52-week-low of $30.44. Evoqua Water Technologies closed at $44.79 at the end of the last trading period.
• According to Raymond James, the prior rating for The Home Depot Inc (NYSE:HD) was changed from Outperform to Market Perform. Home Depot earned $4.24 in the third quarter, compared to $3.92 in the year-ago quarter. The current stock performance of Home Depot shows a 52-week-high of $417.84 and a 52-week-low of $264.51. Moreover, at the end of the last trading period, the closing price was at $311.93.
• According to UBS, the prior rating for Corteva Inc (NYSE:CTVA) was changed from Buy to Neutral. Corteva earned $0.12 in the third quarter, compared to $0.14 in the year-ago quarter. The current stock performance of Corteva shows a 52-week-high of $68.43 and a 52-week-low of $43.74. Moreover, at the end of the last trading period, the closing price was at $66.72.
• According to Keybanc, the prior rating for Rapid7 Inc (NASDAQ:RPD) was changed from Overweight to Sector Weight. In the third quarter, Rapid7 showed an EPS of $0.14, compared to $0.06 from the year-ago quarter. The stock has a 52-week-high of $118.42 and a 52-week-low of $26.48. At the end of the last trading period, Rapid7 closed at $30.92.

See all analyst ratings downgrades.

Initiations

• With an Outperform rating, Evercore ISI Group initiated coverage on Lithium Americas Corp (NYSE:LAC). The price target seems to have been set at $35.00 for Lithium Americas. For the third quarter, Lithium Americas had an EPS of $0.30, compared to year-ago quarter EPS of $0.14. The stock has a 52-week-high of $40.39 and a 52-week-low of $18.89. At the end of the last trading period, Lithium Americas closed at $26.39.
• Truist Securities initiated coverage on AbCellera Biologics Inc (NASDAQ:ABCL) with a Buy rating. The price target for AbCellera Biologics is set to $29.00. AbCellera Biologics earned $0.08 in the third quarter, compared to $0.08 in the year-ago quarter. At the moment, the stock has a 52-week-high of $14.97 and a 52-week-low of $5.42. AbCellera Biologics closed at $14.49 at the end of the last trading period.
• Needham initiated coverage on Altair Engineering Inc (NASDAQ:ALTR) with a Buy rating. The price target for Altair Engineering is set to $60.00. In the third quarter, Altair Engineering showed an EPS of $0.05, compared to $0.11 from the year-ago quarter. The stock has a 52-week-high of $78.38 and a 52-week-low of $43.17. At the end of the last trading period, Altair Engineering closed at $50.07.
• Edward Jones initiated coverage on Synopsys Inc (NASDAQ:SNPS) with a Hold rating. In the third quarter, Synopsys showed an EPS of $2.10, compared to $1.81 from the year-ago quarter. At the moment, the stock has a 52-week-high of $391.17 and a 52-week-low of $255.02. Synopsys closed at $334.20 at the end of the last trading period.
• JMP Securities initiated coverage on Spruce Biosciences Inc (NASDAQ:SPRB) with a Market Outperform rating. The price target for Spruce Biosciences is set to $8.00. For the third quarter, Spruce Biosciences had an EPS of $0.48, compared to year-ago quarter EPS of $0.49. At the moment, the stock has a 52-week-high of $4.69 and a 52-week-low of $0.96. Spruce Biosciences closed at $1.05 at the end of the last trading period.
• RBC Capital initiated coverage on Mind Medicine Inc (NASDAQ:MNMD) with an Outperform rating. The price target for Mind Medicine is set to $5.00. Mind Medicine earned $0.56 in the third quarter, compared to $0.60 in the year-ago quarter. At the moment, the stock has a 52-week-high of $23.10 and a 52-week-low of $2.35. Mind Medicine closed at $2.86 at the end of the last trading period.
• With a Neutral rating, Credit Suisse initiated coverage on Microchip Technology Inc (NASDAQ:MCHP). The price target seems to have been set at $85.00 for Microchip Technology. Microchip Technology earned $1.46 in the second quarter, compared to $1.07 in the year-ago quarter. The stock has a 52-week-high of $88.97 and a 52-week-low of $54.33. At the end of the last trading period, Microchip Technology closed at $76.94.
• Credit Suisse initiated coverage on Monolithic Power Systems Inc (NASDAQ:MPWR) with an Outperform rating. The price target for Monolithic Power Systems is set to $475.00. Monolithic Power Systems earned $3.53 in the third quarter, compared to $2.06 in the year-ago quarter. At the moment, the stock has a 52-week-high of $541.39 and a 52-week-low of $301.69. Monolithic Power Systems closed at $405.03 at the end of the last trading period.
• Credit Suisse initiated coverage on Marvell Technology Inc (NASDAQ:MRVL) with an Outperform rating. The price target for Marvell Tech is set to $56.00. Marvell Tech earned $0.57 in the second quarter, compared to $0.34 in the year-ago quarter. At the moment, the stock has a 52-week-high of $91.78 and a 52-week-low of $35.30. Marvell Tech closed at $44.70 at the end of the last trading period.
• Credit Suisse initiated coverage on NXP Semiconductors NV (NASDAQ:NXPI) with a Neutral rating. The price target for NXP Semiconductors is set to $195.00. For the third quarter, NXP Semiconductors had an EPS of $3.81, compared to year-ago quarter EPS of $2.84. The current stock performance of NXP Semiconductors shows a 52-week-high of $234.90 and a 52-week-low of $132.08. Moreover, at the end of the last trading period, the closing price was at $174.81.
• Credit Suisse initiated coverage on Qualcomm Inc (NASDAQ:QCOM) with an Outperform rating. The price target for Qualcomm is set to $150.00. Qualcomm earned $3.13 in the fourth quarter, compared to $2.55 in the year-ago quarter. The stock has a 52-week-high of $193.58 and a 52-week-low of $101.93. At the end of the last trading period, Qualcomm closed at $126.02.
• Credit Suisse initiated coverage on Micron Technology Inc (NASDAQ:MU) with an Outperform rating. The price target for Micron Technology is set to $78.00. In the fourth quarter, Micron Technology showed an EPS of $1.45, compared to $2.42 from the year-ago quarter. The current stock performance of Micron Technology shows a 52-week-high of $98.45 and a 52-week-low of $48.45. Moreover, at the end of the last trading period, the closing price was at $63.10.

See all analyst ratings initiations.